Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 04, 2023

Biomarker-Driven Risk-Directed Ambulatory Thromboprophylaxis in Patients With Lung and Gastrointestinal Cancers

JAMA Oncology


Additional Info

JAMA Oncology
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial
JAMA Oncol 2023 Sep 21;[EPub Ahead of Print], M Alexander, S Harris, C Underhill, J Torres, S Sharma, N Lee, H Wong, R Eek, M Michael, J Tie, J Rogers, AG Heriot, D Ball, M MacManus, R Wolfe, BJ Solomon, K Burbury

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading